Evvy Surpasses 75,000 Patients, Marking a New Era of Momentum in Vaginal Microbiome-Driven Care

The Pioneer In Precision Women’s Health Reaches New Milestones, Redefining Vaginal Health with Unprecedented Growth and Scientific Breakthroughs

NEW YORK--(BUSINESS WIRE)--Evvy, the world’s leading platform leveraging the vaginal microbiome to improve women’s health outcomes, today announced record growth and new data highlighting the impact of their platform. Evvy now supports over 75,000 patients and 2,000 healthcare providers with its leading vaginal microbiome testing and care platform.

Vaginal discomfort is a leading reason women seek healthcare, and the standard of care leaves women with unacceptably high misdiagnosis (>60%) and recurrence (>50%) rates. Additionally, research highlights the critical role of the vaginal microbiome in modulating inflammation of the reproductive tract across the female lifespan.

Evvy has developed the world’s first and only comprehensive vaginal microbiome test and precision care platform, integrating CLIA/CAP/CLEP-certified metagenomic sequencing, prescription clinical care, and 1:1 health coaching. And new data from Evvy shows that this approach is working:

• For patients who have come to Evvy with previously unsolved vaginal symptoms, 90% identified a potential root cause of their vaginal symptoms with their first Evvy test.
• 75% of asymptomatic patients who came to Evvy after being diagnosed with infertility had a treatable microbiome imbalance discovered by Evvy’s test.
• For 47% of users who reported a recent UTI, Evvy found UTI-related bacteria in the vaginal microbiome, an overlooked contributor to UTI recurrence.
• Evvy has served over 12,000 women interested in their fertility with novel insights on the impact of their vaginal microbiome on their reproductive health.

This data comes off the back of recent peer-reviewed studies on Evvy’s platform highlighting dramatic improvements in patient outcomes and the robust validation of their test.

“What excites me most is that we’re only scratching the surface of the power of the insights in the vaginal microbiome. With every test, treatment, and study, we’re building the evidence base that will redefine care for millions of women — and transform outcomes across infections, fertility, and beyond. Evvy’s work is turning scientific insights into a new standard of care for women’s health.”

Through their platform, Evvy has now built the world’s largest, most comprehensive dataset on the vaginal microbiome, powering discoveries that could reshape the future of IVF, preterm birth prevention, UTI care, gynecologic cancer research, and beyond.

Evvy recently announced their groundbreaking fertility study, uncovering the previously hidden role of the vaginal microbiome in conception and implantation outcomes. Early data suggest that optimizing vaginal microbial balance before conception may improve fertility success rates, a potential breakthrough that could transform fertility care for millions of women.

Looking ahead, Evvy is expanding its precision health platform to explore new frontiers in women’s healthcare, from longitudinal studies on hormonal transitions like menopause to predictive biomarkers for pregnancy outcomes and early disease detection. With its unmatched dataset, growing clinical network, and deeply engaged community, Evvy is building a future where the female body is no longer a medical mystery, but a map for personalized care.

About Evvy

Evvy is closing the gender health gap through novel biomarker discovery in the vaginal microbiome. Evvy’s groundbreaking Vaginal Health Test is the world’s only certified, peer-reviewed vaginal microbiome test to uncover 700+ microbes with a single, at-home swab. Combined with precision treatment pathways and 1-1 coaching, Evvy provides over 75,000 women with data-driven, personalized healthcare for vaginal infections, fertility, menopause, and more. Evvy has built the world’s largest dataset on the vaginal microbiome, and they are pioneering novel research to transform female health outcomes.